Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Wang, Wei Ming ^a,b   Zhao, Zhi Li ^a,b   Ma, Si Rui ^a,b   Yu, Guang Tao ^a   Liu, Bing ^b   Zhang, Lu ^a   Zhang, Wen Feng ^b   Kulkarni, Ashok B ^c   Sun, Zhi Jun ^a,b   Zhao, Yi Fang ^a,b  

^a WUHAN UNIVERSITY   (China)

^b Wuhan University   (China)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN A; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY DENSITY; CHEMOPROPHYLAXIS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GROWTH INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CETUXIMAB; HEAD AND NECK NEOPLASMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1;

EID: 84923818154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119723     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. Ca-Cancer J Clin. 2011; 61:69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Zini A, Czerninski R, Sgan-Cohen HD. Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med. 2010; 39:299-305. doi: 10.1111/j.1600-0714. 2009.00845.x PMID: 20040019
3. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11:21-8. doi: 10.1016/S1470-2045(09)70311-0 PMID: 19897418
4. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013; 14:257-64. doi: 10.1016/S1470-2045(13)70011-1 PMID: 23414589
5. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1 alpha Level Is Essential for Hematopoietic Stem Cells. Cell Stem Cell. 2010; 7:391-402. doi: 10.1016/j.stem.2010.06.020 PMID: 20804974
6. Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, et al. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila). 2011; 4:230-7. doi: 10.1158/1940-6207. CAPR-10-0249 PMID: 21163936
7. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006; 24:2666-72. PMID: 16763281
8. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62:7350-6. PMID: 12499279
9. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013; 3:761-9. doi: 10.1158/2159-8290.CD-13-0103 PMID: 23619167
10. Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA. Mol Pharmacol. 2012; 81:527-40. doi: 10.1124/mol.111.076851 PMID: 22219388
11. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359:1116-27. doi: 10.1056/NEJMoa0802656 PMID: 18784101
12. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chien CRC, Makhson A, et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New Engl J Med. 2009; 360:1408-17. doi: 10.1056/NEJMoa0805019 PMID: 19339720
13. Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, et al. A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. Clin Cancer Res. 2008; 14:6277-83. doi: 10.1158/1078-0432.CCR-08-0482 PMID: 18829509
14. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011; 475:226-30. doi: 10.1038/nature10169 PMID: 21753853
15. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333:1157-60. doi: 10.1126/science.1208130 PMID: 21798893
16. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154-7. doi: 10.1126/science.1206923 PMID: 21798897
17. Wang XJ, Feng CW, Li M. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 2013; 380:57-66. doi: 10.1007/s11010-013-1657-z PMID: 23625205
18. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, et al. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancerrelated inflammation. Oncogene. 2012; 31:3322-32. doi: 10.1038/onc.2011.494 PMID: 22037217
19. Zhang L, Sun ZJ, Bian YS, Kulkarni AB. MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma. Cancer Lett. 2013; 331:230-8. doi: 10.1016/j.canlet.2013.01.003 PMID: 23340180
20. Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res. 2012; 18:5304-13. doi: 10.1158/1078-0432.CCR-12-1371 PMID: 22859719
21. Bian Y, Terse A, Du J, Hall B, Molinolo A, Zhang P, et al. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 2009; 69:5918-26. doi: 10.1158/0008-5472.CAN-08-4623 PMID: 19584284
22. Sun ZJ, Chen G, Zhang W, Hu XA, Huang CF, Wang YF, et al. Mammalian Target of Rapamycin Pathway Promotes Tumor-Induced Angiogenesis in Adenoid Cystic Carcinoma: Its Suppression by Isoliquiritigenin through Dual Activation of c-Jun NH2-Terminal Kinase and Inhibition of Extracellular Signal-Regulated Kinase. J Pharmacol Exp Ther. 2010; 334:500-12. doi: 10.1124/jpet.110.167692 PMID: 20484154
23. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012; 18:2336-43. doi: 10.1158/1078-0432.CCR-11-2825 PMID: 22371453
24. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol. 2008; 73:1632-42. doi: 10.1124/mol.107.044636 PMID: 18326051
25. Wu X, Bhayani MK, Dodge CT, Nicoloso MS, Chen Y, Yan X, et al. Coordinated targeting of the EGFR signaling axis by microRNA-27a∗. Oncotarget. 2013; 4:1388-98. PMID: 23963114
26. Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res. 2010; 16:2095-105. doi: 10.1158/1078-0432.CCR-09-2495 PMID: 20215534
27. Chen M, Glenn JV, Dasari S, McVicar C, Ward M, Colhoun L, et al. RAGE regulates immune cell infiltration and angiogenesis in choroidal neovascularization. PLoS One. 2014; 9:e89548. doi: 10.1371/journal.pone.0089548 PMID: 24586862
28. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012; 72:2162-71. doi: 10.1158/0008-5472.CAN-11-3687 PMID: 22549946
29. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407:249-57. PMID: 11001068
30. Liao YF, Wang BJ, Hsu WM, Lee H, Liao CY, Wu SY, et al. Unnatural amino acid-substituted (hydroxyethyl) urea peptidomimetics inhibit gamma-secretase and promote the neuronal differentiation of neuroblastoma cells. Mol Pharmacol. 2007; 71:588-601. PMID: 17105873
31. Arumugam TV, Cheng YL, Choi Y, Choi YH, Yang S, Yun YK, et al. Evidence that gamma-Secretase-Mediated Notch Signaling Induces Neuronal Cell Death via the Nuclear Factor-kappa B-Bcl-2-Interacting Mediator of Cell Death Pathway in Ischemic Stroke. Mol Pharmacol. 2011; 80:23-31. doi: 10.1124/mol.111.071076 PMID: 21450930
32. Troy JD, Weissfeld JL, Youk AO, Thomas S, Wang L, Grandis JR. Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Head Neck Pathol. 2013; 7:344-55. doi: 10.1007/s12105-013-0447-y PMID: 23645351
33. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell. 2009; 16:196-208. doi: 10.1016/j.devcel.2009.01.015 PMID: 19217422
34. Soares R, Balogh G, Guo S, Gartner F, Russo J, Schmitt F. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol. 2004; 18:2333-43. PMID: 15192074
35. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011; 71:6073-83. doi: 10.1158/0008-5472.CAN-11-1704 PMID: 21803743
36. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008;68:4727-35. doi: 10.1158/0008-5472.CAN-07-6499 PMID: 18559519
37. Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci. 2009; 14:3094-110. PMID: 19273260
38. Hayashi H, Kume T. Foxc Transcription Factors Directly Regulate Dll4 and Hey2 Expression by Interacting with the VEGF-Notch Signaling Pathways in Endothelial Cells. PLoS One. 2008;3.
39. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006; 66:2778-84. PMID: 16510599